微信公众号:蹊之美股生物医药 / CaesarBiotech
Gainers:
Profound Medical (NASDAQ:PROF) +29%
STAAR Surgical (NASDAQ:STAA) +20%
AdaptHealth (NASDAQ:AHCO) +15%
Flora Growth (NASDAQ:FLGC) +12%
Invacare (NYSE:IVC) +14%
L...查看全文
郁闷的鞋套-2021-07-20 12:42
$Nevro(NVRO)$ 2021年7月19日,Nevro公司宣布,其专有的10 kHZ脊髓刺激(SCS)“Senza”系统,已获得美国FDA批准,用于治疗疼痛性糖尿病神经病变(PDN)引起的慢性疼痛。新闻稿指出,这是FDA批准的首款以PDN为适应症的脊髓刺激系统。该公司将根据本次批准,推出的名为“HFX”的PDN治疗相关产品。HF...查看全文
智通财经APP获悉,鉴于多数大型医疗科技公司已公开表示有意在该领域进行收购,摩根大通分析师Robbie Marcus列出了潜在的收购目标,包括:英特格拉生命科学(IART.US)、Nevro (NVRO.US)、纽瓦索器材(NUVA.US)、Silk Road Medical (SILK.US... 网页链接
$Nevro(NVRO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001564590-20-051332 Act: 34 Size: 561 KB 网页链接
$Nevro(NVRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001567619-20-018618 Size: 4 KB 网页链接
$Nevro(NVRO)$ 内部交易: 2020-10-22,Chief Commercial Officer,Pellegrini Niamh Louise ,卖出,1817普通股, $165.00
$Nevro(NVRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001567619-20-018184 Size: 4 KB 网页链接
$Nevro(NVRO)$ 内部交易: 2020-10-19,Chief Commercial Officer,Pellegrini Niamh Louise ,卖出,1000普通股, $155.00
$Nevro(NVRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001567619-20-018057 Size: 4 KB 网页链接
$Nevro(NVRO)$ 内部交易: 2020-10-12,Director,DEMANE MICHAEL F ,卖出,903普通股, $151.21
$Nevro(NVRO)$ 内部交易: 2020-10-09,Director,DEMANE MICHAEL F ,卖出,20529普通股, $150.31
$Nevro(NVRO)$ 内部交易: 2020-10-09,Chief Commercial Officer,Pellegrini Niamh Louise ,卖出,1000普通股, $150.00
$Nevro(NVRO)$ 内部交易: 2020-10-13,Chief Commercial Officer,Pellegrini Niamh Louise ,卖出,750普通股, $151.47